Pancreatic Cancer Research

ResearcherStony Brook UniversityNo recent work listed

Michael J. Hayman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9245-1583; OpenAlex author ID A5018779172; NIH RePORTER profile ID 6213818. Sources: OpenAlex.

Their work

Papers
2 (first author 0, last author 1)
Trials
0
Grants
1
Labs led
1
Collaborators
3
Papers, trials and grants by year

2014: 1 grant · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper

Papers 2

  1. KRAS drives immune evasion in a genetic model of pancreatic cancer. Co-author DOI 10.1038/s41467-021-21736-w↗
  2. A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells. Last author DOI 10.18632/oncotarget.4538↗

Grants 1

  1. HDAC3 - a therapeutic target in PDA R21CA170041↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Irene Ischenko · 2 shared papers, 2015–2021 · strength 0.22
  2. Stephen D’Amico · 1 shared paper, 2021 · strength 0.14
  3. Nancy C. Reich Marshall · 1 shared paper, 2021 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.